RecruitingPhase 4NCT05682131

South China Children Cancer Group - Relapsed-Acute Lymphoblastic Leukemia 2022 Protocol


Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Enrollment

210 participants

Start Date

Sep 27, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

In recent years, the prognosis of pediatric relapsed ALL patients has improved, but the 5-year OS of patients with first recurrence is still less than 50%. A number of in vitro studies have shown that arsenic trioxide (ATO) can selectively inhibit the growth and induce apoptosis in a variety of leukemia cell lines, suggesting that ATO as a synergist combined with other common chemotherapy drugs may provide a new target for the treatment of relapsed ALL. Realgar Indigo naturalis formula is a compound traditional Chinese medicine preparation developed in China. The main component of realgar is arsenic tetrasulfide (As4S4), which can produce similar pharmacological effects to ATO. Based on the R3 protocol, this study plans to perform a double-blind randomized controlled trial, and to randomly combine compound Huangdai tablets with compound Huangdai tablets in the treatment of intermediate and high risk ALL children, in order to improve the MRD negative rate after induction therapy in this group of children, which may provide a new method for the clinical treatment of relapsed ALL.


Eligibility

Min Age: 1 YearMax Age: 14 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a treatment protocol for children with relapsed (returned) acute lymphoblastic leukemia (ALL) — a blood cancer — under a collaborative research group in South China. It focuses specifically on children experiencing their first relapse who are classified as medium or high risk. **You may be eligible if...** - Your child has been diagnosed with B-cell or T-cell acute lymphoblastic leukemia - This is your child's first relapse - Your child's relapse has been classified as medium or high risk **You may NOT be eligible if...** - Your child has mature B-cell leukemia or mixed phenotype leukemia - Your child's leukemia is positive for the BCR-ABL gene (Philadelphia chromosome) - Your child has Down syndrome - This is a second cancer (not the first leukemia) - Your child's condition is a blast crisis from chronic myeloid leukemia (CML) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRealgar Indigo naturalis formula

Realgar Indigo naturalis formula was used in the induction, consolidation and intensive treatment of patients in intermediate or high risk

COMBINATION_PRODUCTConventional chemotherapy

conventional chemotherapy


Locations(1)

Sun Yat-sen Memorial Hospital, Sun Yat-sen University

Guangzhou, Guangdong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05682131


Related Trials